表紙
市場調查報告書

器官晶片的革新推動藥物研發篩檢用途

Organ-On-A-Chip Innovations Fueling Drug Screening Applications

出版商 Frost & Sullivan 商品編碼 662141
出版日期 內容資訊 英文 70 Pages
商品交期: 最快1-2個工作天內
價格
器官晶片的革新推動藥物研發篩檢用途 Organ-On-A-Chip Innovations Fueling Drug Screening Applications
出版日期: 2018年06月29日內容資訊: 英文 70 Pages
簡介

新的器官晶片平台有可能改變製藥產業的藥物研發篩檢流程。

本報告提供器官晶片的革新調查分析,提供技術概要,現狀,推動因素與課題,主要企業,IP形勢,成長機會等系統性資訊。

第1章 摘要整理

第2章 科技概述

  • 器官晶片功能概要
  • 藥物研發篩檢流程上器官晶片技術的主要促進因素
  • 器官晶片平台的現在趨勢

第3章 器官晶片平台

  • 心臟晶片平台
  • 肝臟晶片平台
  • 肺晶片平台
  • 腎臟晶片平台
  • 腸晶片平台
  • 神經晶片平台
  • 肌肉晶片平台
  • 腦晶片平台
  • 多器官晶片平台
  • 人體晶片平台

第4章 器官晶片技術的推動因素與課題

  • 影響器官晶片技術的推動因素與課題
  • 器官晶片技術
  • 幹細胞

第5章 主要器官晶片企業

  • CN Bio
  • Emulate
  • Hesperos
  • ParVivo
  • TissUse等

第6章 器官晶片技術的IP形勢

  • 專利範圍和概念
  • 器官晶片平台的發明專利權者 (前20名)
  • 器官晶片專利組合的分佈 (各專利事務所)
  • 器官晶片專利組合的專利公開分佈 (各年度)

第7章 器官晶片技術的資金形勢

  • 器官晶片技術的資金力:全球分析
  • 器官晶片開發的政府資金
  • 器官晶片市場上VC為主的投資資金
  • 無動物實驗研究器官晶片技術開發上的資金

第8章 成長機會

  • 成長機會1
  • 成長機會2
  • 成長機會3
  • 影響藥物研發篩檢流程的器官晶片平台決策要素

第9章 附錄

目錄
Product Code: D84A

Novel Organ-chip Platforms Likely to Transform the Drug Screening Process in the Pharmaceutical Industry

Organ-on-a-chip technology involves the incorporation of microphysiological systems harboring dynamic living 3D organoids, tissue-culture, or cell cultures on a microfluidic platform. The physiologically relevant Organ-chip models offer a better and more precise insight to the possible in vivo effects of drugs in the human body. The flexibility of Organ-on-a-chip is such that the innovation is not just human relevant per se but can mimic a wide variety of human functions such as breathing, heart beats, peristalsis, menstruation, neuronal communication.

Animal models and in vitro assays have served as the gold standard for pre-clinical research and study for a long time now. But for all the benefits, animal models and in vitro assays have seen poor results in human translation and prediction due to unsatisfactory human relevance. Organ-on-a-chip innovations are currently making themselves relevant by offering better data for human translation and prediction through their high degree of human relevant systems.

US are currently the frontrunners in the Organ-on-a-chip technology followed closely by Netherlands, United Kingdom and Germany. The countries have been capitalized on the need for a better study model in drug screening application to pioneer the development of Organ-on-a-chip innovations which has seen relative success in the pharmaceutical industry as evidenced by the adoption of Organ-chip technology by major pharmaceutical companies such as Roche, AstraZeneca among many others.

Table of Contents

1.0. EXECUTIVE SUMMARY

  • 1.1. Research Scope - Application of Organ-on-a-chip Technology in Drug Screening Process
  • 1.2. Research Methodology - The Frost & Sullivan Core Value
  • 1.3. Key Findings: Organ-on-a-chip Technology

2.0. TECHNOLOGY SNAPSHOT

  • 2.1. A Brief Overview of Organ-on-a-chip Functioning
  • 2.2. Key Factors Empowering Organ-on-a-chip Technologies for Drug Screening Processes
  • 2.3. Current Trends in the Organ-on-a-chip platform

3.0. ORGAN-ON-A-CHIP PLATFORMS

  • 3.1. Heart-on-a-chip Platform
  • 3.2. Liver-on-a-chip Platform
    • 3.2.1. High Throughput Capability of Liver-on-a-chip Platforms Integral to Large-Scale Drug Screening Applications
    • 3.2.2. Flow Systems Adopted in Liver-on-a-chip Platforms that Facilitate Stability
  • 3.3. Lung-on-a-chip Platform
    • 3.3.1. Lung-on-a-chip: Platform Overview, Application, Disadvantages and Features
  • 3.4. Kidney-on-a-chip Platform
    • 3.4.1. Kidney-on-a-chip: Features, Platform Design, Applications, and Challenges
  • 3.5. Gut-on-a-chip/Intestine-on-a-chip Platform
    • 3.5.1. Intestine- and Gut-on-a-chip Serve as Enhanced Study Models
    • 3.5.2. Intestine- and Gut-on-a-chip: The Applications and the Challenges
  • 3.6. Nerve-on-a-chip Platform
    • 3.6.1. Evaluation of Neurotoxicity with Nerve-on-a-chip platform
  • 3.7. Muscle-on-a-chip Platform
    • 3.7.1. Muscle-on-Chip Platform to Determine Long-term rug ffects on Muscle Loss and Toxicity
    • 3.7.2. Muscle-on-a-chipPhysiology, Features and Application Areas
  • 3.8. Brain-on-a-chip Platform
    • 3.8.1. Emulation of Human-Blood-Brain Barrier
  • 3.9. Multi-Organ Chip Platforms
  • 3.10. Human-on-a-chip Platform

4.0. DRIVERS AND CHALLENGES OF ORGAN-CHIP TECHNOLOGY

  • 4.1. Drivers and Challenges Impact Chart of Organ-Chip Technology
  • 4.2. Organ-on-a-chip Technology
  • 4.3. Stem ell henotypes key to unlocking vast otential of Organ-chip Systems

5.0. MAJOR ORGAN-ON-A-CHIP COMPANIES

  • 5.1. A Well-defined and Robust Nerve-on-a-chip Platform
  • 5.2. CN Bio- UK's Organ-chip Technology Pioneer
  • 5.3. Emulate propelling Drug Screening and Development through their
  • 5.4. Hesperos facilitates superior Serum-free Media and Pumpless Organ-Chip Systems
  • 5.5. Liver-on-a-chip platforms with High Biological Fidelity
  • 5.6. Scaffold-free Human Relevant Liver-on-a-Chip Systems
  • 5.7. Validated Research-ready Organ-chip Systems
  • 5.8. Organ-Chips that facilitate High Throughput Screening
  • 5.9. Precise Flow-controlled ParVivo Organ-Chip Systems
  • 5.10. Replicating In Vivo Cardiac Biology on an n Vitro Chip Platform
  • 5.11. TissUse pioneering Human-on-a-Chip platform

6.0. INTELLECTUAL PROPERTY LANDSCAPE OF ORGAN-ON-A-CHIP TECHNOLOGY

  • 6.1. Patent Research Scope and Concepts
  • 6.2. Top 20 Patent Holders in the Organ-on-a-chip Platform
  • 6.3. Patent Office-wise Distribution of Organ-on-a-chip Patent Portfolio, 2008-2018*
  • 6.4. Year-wise Publication Distribution of Organ-on-a-chip Patent Portfolio, 2008-2017

7.0. FUNDING LANDSCAPE OF ORGAN-ON-A-CHIP TECHNOLOGY

  • 7.1. Funding Strength of Organ-Chip Technology- Global View
  • 7.2. Government Funding for Organ-on-a-chip Development
  • 7.3. Venture Capitalist-based Investment Funding in the OOC Market
  • 7.4.Animal Free Research involved in Funding of Organ-on-a-chip Technology Development

8.0. GROWTH OPPORTUNITIES

  • 8.1. Growth Opportunity 1: Personalized Medicine
  • 8.2. Growth Opportunity 2: Animal Model Replacement
  • 8.3. Growth Opportunity 3: Identification of Biomarkers
  • 8.4. Determinants of Organ-on-a-chip Platform's Impact on Drug Screening Process

9.0. APPENDIX

  • 9.1. Key Contacts
  • 9.1. Key Contacts (continued)
  • Legal Disclaimer